Grant ID

10T-1416

Illness

schizophrenia

Primary Drug/Intervention

raloxifene

Primary Dosage

120 mg/day

Secondary Drug Intervention

N/A

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Weiser

Sample Size

200

Duration of Study Period for Each Subject

16 weeks

Outcome Measurements

N/A

Results

Baseline means in PANSS total scores were 101.7+/-18.5 for raloxifene and 101.2 +/-18.1 for placebo; the mean change between baseline and end of study were -16.2+/-13.1 for raloxifene and -19.2+/-15.1 for placebo. The difference between groups was non-significant.

Publication

In progress.

Link

N/A

PI Name

Mark Weiser

Degree

MD

Center

Sheba Medical Center

Institution

N/A

Address

City or Town

Tel Hashomer

State or Province

N/A

Zip or Postal Code

52621

Country

Israel

Email Address

mweiser@netvision.net.il